Shares of Aeterna Zentaris (AEZS 2.57%) were gutted on the market Monday, down 25% intraday. In this video, Motley Fool health-care analyst David Williamson takes a look at a horrendous 12-month period for the company overall, and how hanging its hopes on its drug Perifosine has resulted in disappointment after disappointment in clinical trials.
Breakdown of This Biotech Massacre
By Dave Williamson – Mar 11, 2013 at 5:52PM
OTC: AEZS
Cosciens Biopharma
Market Cap
$8.2M
Today's Change
(-2.57%) $0.07
Current Price
$2.50
Price as of October 23, 2025 at 3:49 PM ET
Why Wall Street ran red with this biotech's blood today.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid